| P/E (FY) | — | Sales (TTM) | $79.6M |
| Earnings (TTM) | -$37.3M | ROE | −50.74% |
| Net Margin | −49.67% | ROIC | −311.81% |
| Debt / Equity | 0.63 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 2.74% |
| Market Cap | $288.4M | Trading Days | 1258 |
| 52W High | 9.24 |
| 52W Low | 3.11 |
| % Off High | −42.62% |
| YTD | −33.17% | 1Y | 49.72% |
| 3Y | −39.70% | 5Y | −85.38% |
| Since incept. (ann.) | −30.34% |
Surgical Glaucoma 98% · Dry Eye 2%
| Ann. Volatility (1Y) | 82.57% | Ann. Volatility (3Y) | 97.17% |
| Sharpe (1Y) | 0.90 | Sharpe (3Y) | 0.40 |
| Max Drawdown (1Y) | −61.88% | Max Drawdown (3Y) | −85.34% |
| Beta (3Y, vs SPY) | 4.12 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PSTV | PLUS THERAPEUTICS, INC. | $292.5M | — |
| OSUR | ORASURE TECHNOLOGIES INC | $276.8M | — |
| TLSI | TriSalus Life Sciences, Inc. | $265.9M | — |
| TMCI | TREACE MEDICAL CONCEPTS, INC. | $264.7M | — |
| PROF | Profound Medical Corp. | $263.4M | 5.1 |
| CARL | CARLSMED, INC. | $334.6M | — |
| OBIO | Orchestra BioMed Holdings, Inc. | $231.1M | — |
| UTMD | UTAH MEDICAL PRODUCTS INC | $225.9M | 20.4 |
| MOBI | Mobia Medical, Inc. | $370.1M | — |
| EMBC | Embecta Corp. | $213.0M | 2.2 |
| DCTH | DELCATH SYSTEMS, INC. | $398.7M | 165.0 |
| PMI | Picard Medical, Inc. | $405.8M | — |
